Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 25Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Mesothelioma 2Stomach Neoplasms 1Sarcoma 1SCLC, Extensive Stage 1Recurrence 1Ovarian Neoplasms 1Neutropenia 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cisplatin 6Etoposide 5Topotecan 4Carboplatin 4Pemetrexed 3Gemcitabine 3belinostat 2Temozolomide 2RRx-001 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pembrolizumab 1lurtotecan 1liposomal doxorubicin 1enzalutamide 1bemiparin 1belotecan 1atezolizumab 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Sorafenib 1Rhenium 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × PM 01183 × Thoracic × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡